$EPRT

[144] ESSENTIAL PROPERTIES REALTY TRUST, INC. SEC Filing

This SEC filing ([144] Essential Properties Realty Trust, Inc.) indicates a proposed sale of 5,851 shares of common stock by an insider, acquired through RSU vesting on January 18, 2026. The shares have an aggregate market value of $186,412.86 and are intended to be sold on the NYSE on March 20, 2026. This is a routine filing for an insider intending to sell securities.

Original reporting
Published Mar 20, 2026, 4:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Mar 20, 2026, 5:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$EPRT
Neutral
medium confidence
Mentioned
$EPRT
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$EPRTNeutralLow
01

Why it matters

The insider sale is routine and unlikely to influence the company's stock price significantly.

02

Market read

Limited impact on market perception; the transaction is routine insider activity.

03

What to watch

Insider sales can also be routine and unrelated to company performance; consider broader fundamentals and market conditions.

Timing: Immediate, as the sale is scheduled for March 20, 2026

Background

EPRT is a real estate investment trust focused on retail and industrial properties, with insider activity indicating normal portfolio management.

Company-level read

Ticker impact

$EPRTNeutralMedium confidence
Context

The news pertains directly to EPRT, a real estate investment trust, and involves insider activity which can influence stock perception.

Expected impact

Minimal short-term impact; potential slight decrease due to insider selling, but unlikely to affect long-term valuation.

Evidence & confidence

Insider sales are common and do not necessarily indicate negative outlook; the transaction is routine.

Market effects

The sale is within the real estate sector, suggesting no immediate sector-wide concerns.

Limited regional impact; specific to EPRT and its market area.

Negligible; focused on a single REIT.

Counterpoint

Some investors might interpret insider sales as a sign of upcoming liquidity needs or profit-taking, potentially signaling caution.

Key entities

  • Essential Properties Realty Trust, Inc.

    A REIT investing in retail and industrial properties.

Related articles

$EPRTMed

ESSENTIAL PROPERTIES REALTY TRUST, INC. (EPRT): Results of Operations and Financial Condition

ESSENTIAL PROPERTIES REALTY TRUST, INC. (EPRT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsreleaseex991-worki.htm EX-99.1 Document Exhibit 99.1 Essential Properties Announces Second Quarter 2026 Results - Second Quarter Net Income per Share of $0.34 and AFFO per Share of $0.50 - - Closed Investments of $332.4 million at a 7.8% Weighted Average Cash Ca

$BAHighAI 9/10

Boeing wins $13.4 billion contract modification from US military

Boeing Co. received a $13.4 billion contract modification from the U.S. Department of War, raising the total contract value to $19.1 billion. The contract, originally awarded in 2019, includes Foreign Military Sales work for Japan, Israel, and future partners. Work will be completed in Seattle by April 28, 2035, with no funds allocated at the time of the award.

$CFGMed

Fitch upgrades Citizens Financial rating on profitability

Fitch upgraded Citizens Financial Group (CFG) and Citizens Bank to 'A-' from 'BBB+', citing improved earnings and profitability. The upgrade reflects margin expansion, stable credit costs, and growth in fee-generating businesses. CFG's non-interest income was 28% of revenue in H1 2026, with wealth management and capital markets revenue up 16% and 52% YoY, respectively. The impaired loan ratio was stable at 1.8%, and the CET1 ratio was 10.4% in Q2 2026.

$AZNHighAI 8/10

AstraZeneca breast cancer drug fails late-stage trial goal

AstraZeneca's breast cancer drug, Etcamah, failed to meet the primary endpoint in a late-stage trial, causing a 3% drop in its U.S.-listed shares. The trial tested the drug in combination with palbociclib for advanced breast cancer. AstraZeneca plans to share full trial data later. The FDA recently granted accelerated approval for Etcamah with certain targeted cancer medicines.

$HRLMed

S&P Global downgrades Hormel Foods outlook on high leverage

S&P Global Ratings revised Hormel Foods' outlook to negative from stable, citing high leverage at 1.8x, above expectations. The firm forecasts modest improvement to 1.7x in 2027 and 1.6x in 2028. Hormel's EBITDA margins have fallen to under 11% due to rising input costs and operational issues. The company is divesting lower-margin assets, but S&P notes these have not significantly reduced debt. A lower rating is possible if leverage does not improve.

$MSFTLow

Microsoft communications boss Frank Shaw leaving after nearly 30 years

Microsoft's communications boss Frank Shaw is leaving after nearly 30 years, according to a memo. Shaw, 64, has been in his role for 17 years and played a major role in shaping Microsoft's external communications. His departure comes as Microsoft undergoes changes, focusing on AI and cloud computing. Microsoft's Azure cloud business crossed $100 billion in annual revenue, driven by AI demand.